DDX3X loss is an adverse prognostic marker in diffuse large B-cell lymphoma and is associated with chemoresistance in aggressive non-Hodgkin lymphoma subtypes

Change log
Kizhakeyil, Atish 
Zaini, Nurmahirah Binte Mohammed 
Poh, Zhi Sheng 
Wong, Brandon Han Siang 
Loh, Xinpeng 

Funder: addenbrooke's charitable trust, cambridge university hospitals; doi: http://dx.doi.org/10.13039/501100002927

Letter to the Editor, DDX3X mutation, Hematolymphoid malignancy, Prognosis, Tumour metastasis, Drug resistance
Is Part Of
nanyang technological university (L0412290)
ministry of education - singapore (MOE2017-T2-2-004)
national medical research council (OFLCG18May-0028, NMRC/TA/0051/2016)
kay kendall leukaemia fund (KKL649)
medical research council (MR/M008584/1)
wellcome trust (203151/Z/16/Z)
cancer research uk (A25117)